الفهرس 
Dialyzer membranesOnly 14 pages are availabe for public view
 |  | from | 98 |  |  |
| | | from | 98 | | |
Abstract
Hyperphosphatemia is highly prevalent in hemodialysis (HD) and peritoneal dialysis (PD) patients and is a major risk factor for cardiovascular mortality.
Hyperphosphataemia is putting patients at significant risk of secondary hyperparathyroidism, vessel and soft tissue calcifications, and death. Hyperphosphataemia has also been linked to haemodynamic disturbances such as hypertension, coronary calcifications, and LVH, which are discussed to contribute significantly to the high incidence of cardiac death in the dialysis population.
Elimination of inorganic phosphate by dialysis is a cornerstone of the management of hyperphosphatemia. Phosphate clearance during HD is affected by various factors of dialysis prescription, such as blood and dialysate flow rate, dialyzer membrane surface area and ultrafiltration volume.
Conventional dialysis utilizing high-flux dialysers removes close to 30 mmol phosphate during a 4 h treatment.In order to reduce hyperphosphataemia, with the knowledge that patients’ compliance to reduced phosphate diet prescriptions and phosphate binders intake is unsatisfactory, enhanced removal is required by HD.
Enhanced phosphate removal by HD must not be dismissed and quantification of phosphate removed by dialysis is mandatory to analyse phosphate balance
The present study showed that Mass phosphate clearance by the high-flux group is higher than of the low-flux group though only no significant difference.